NEW YORK — Agena Bioscience said on Wednesday that it has signed an exclusive distribution deal for its MassArray platform and related products in the Middle East, Africa, and Central Asia with Alliance Global.
According to Agena, the deal covers its MassArray mass spectrometry-based platform for genetic variant measurement, genetic testing applications on the system, and certain other products.
Additional terms were not disclosed.
"With their extensive biomedical distribution network, [Alliance Global] is an ideal partner to bring our high-throughput, low-cost, targeted genetic analysis solution to these emerging healthcare markets," Roman Haehn, senior VP of commercial operations at Agena, said in a statement.
Earlier this month, Agena launched a SARS-CoV-2 variant panel that runs on the MassArray system. The San Diego-based company also recently received Emergency Use Authorization from the US Food and Drug Administration for a MassArray SARS-CoV-2 test.